.Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CD06_Rimegepant.Rimegepant .Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CD06_Rimegepant.Rimegepant| name: | Rimegepant | |
| ATC code: | N02CD06 | route: | oral |
| compartments: | 2 | |
| dosage: | 75 | mg |
| volume of distribution: | 120 | L |
| clearance: | 14.7 | L/h |
| other parameters in model implementation | ||
Rimegepant is an orally administered, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute and preventive treatment of migraine in adults. It is an FDA-approved medication that reduces the occurrence and severity of migraine attacks by blocking the binding of CGRP to its receptor.
Pharmacokinetic parameters reported in healthy adult subjects after administration of a single oral dose in the fasted state.
Li, Y, et al., & Lu, Z (2023). Pharmacokinetics and Safety of Single and Multiple Daily Dosing of 75-mg Rimegepant Orally Disintegrating Tablets in Healthy Chinese Adults: A Randomized Placebo-Controlled Trial. Clinical pharmacology in drug development 12(6) 594–601. DOI:10.1002/cpdd.1230 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36808268